Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Buparlisib with fulvestrant for postmenopausal women with metastatic oestrogen-receptor positive, HER2 negative breast cancer – third line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Breast cancer is the most common cancer in the UK. Most women who get breast cancer are over 50 years of age and have already gone through the menopause.
There are many types of breast cancer. Buparlisib is a new treatment for one type that is called oestrogen receptor positive, HER2 negative breast cancer, and is for patients whose cancer has continued to grow despite hormone treatments. Buparlisib is given as a tablet taken daily. It is given in combination with fulvestrant, a drug which is injected directly into the muscle, and is already widely used for breast cancer. Both drugs are given twice for the first month of treatment, and then given once a month. Studies at the moment are aiming to show how well these treatments work together and that buparlisib is safe to use.
If buparlisib is licenced for use in the UK, it will provide a new treatment option for this patient group. Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms; Estradiol; Estrogens; Female; Humans; Postmenopause Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000744 Date abstract record published 14/06/2016 |